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ABSTRACT
In this paper we report the stepwise preparation and the characterization of new unsymmetrical monoanionic
Ru(III) dinuclear compounds, [NH4][{trans-RuCl4(Me2SO-S)}(la-L){mer-RuCI3(Me2SO-S)(MeSO-O)} (L
pyz (1), pym (2)). By a similar synthetic approach we also prepared new mixed-valence Ru(III)/Ru(II)
dinuclear compounds of formula [NH4][{trans-RuCl4(Me2SO-S)}(t-pyz){cis, cis,cis-RuCl2(Me2SO-
S)2(CO)}] (L pyrazine (pyz, 3), pyrimidine (pym, 4)). Moreover, we describe the chemical behavior of
compounds 1-4 in physiological solution, also after complete reduction (with ascorbic acid) to the
corresponding Ru(II)/Ru(II) species. Overall, the chemical behavior of I and 2 after reduction resembles that
of the corresponding dianionic and neutral dinuclear species, [{trans-RuCl4(Me2SO-S)}(t-L)]
2 and [{mer-
RuCI3(Me2SO-S)(Me2SO-O)}2(-L)]. On the other hand, the mixed-valence dinuclear compounds 3 and 4,
owing to the great inertness of the cis, cis,cis-RuCl2(Me2SO-S)2(CO)(1/2-L) fragment, behave substantially
like the mononuclear species [trans-RuC14(Me2SO-S)(L)]" in which the terminally bonded L ligand can be
considered as bearing a bulky substituent on the otherN atom.
INTRODUCTION
The introduction of the Ru(IlI)-dimethylsulfoxide complex ImH[trans-RuCl4(Me2SO-S)Im] (NAMI-
A, Im imidazole, [1]) into phase I clinical trials as antimetastatic drug (October 1999) prompted us to
investigate also other closely related ruthenium compounds. Within this frame, stimulated by the excellent
results obtained by the platinum antieaneer dimers and trimers developed by Farrell [2], we prepared also
symmetrical dinuclear ruthenium(III)species, either dianionic [Na]z[{trans-RuCl4(MezSO-S)}z(t-L)] (a), or
neutral [{mer-RuCl3(MezSO-S)(Me2SO-O)}zOt-L)] (b), with L bridging heterocyelic N-donor ligand such
as pyrazine (pyz), pyrimidine (pym), 4,4’-bipyridine (bipy) and derivatives thereof (Figure 1) [3].
SOMe2
CI,,.... ..C!
N
Ci,......
1
C!-" u’,C!
SOMe2
(a)
SOMe2
Ci,,.... .,,,OSMe2
N
CI,......3 ......,OSMe2
CI’]Uci
SOMe2
(b)
Figure 1. Schematic representation ofthe dianionic (a) and neutral (b) symmetrical dimers described in ref 3.
The coordination environment of each ruthenium(III) center in the dianionic species a is essentially
the same as in the mononuclear compound NAMI-A (four trans chlorides, one S-bonded dimethylsulfoxide
and one heterocyclic N-ligand). Preliminary results from in vivo tests on the murine MCa carcinoma model
showed that some of the dianionic species were as effective as NAMI-A in reducing the spontaneous
metastases (to about 5% with respect to controls) at a dosage 3.5 times lower in terms of ruthenium compared
to that normally used for NAMI-A [4]. The neutral dinuclear compounds b, based on the known chemical
behavior of the corresponding mononuclear species mer-RuCI3(Me2SO-S)(MezSO-O)(L) [5], are expected toE. Alessio et aL Novel Unsymmetrical Ru(III) andMixed-Valence Ru(III)/Ru(II)
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behave differently compared to the dianionic analogs a and might therefore give different biological
responses as well; however, they could not be tested owing to very low solubility in aqueous solution.
We thought thus of combining the chemical environments of both neutral and dianionic species and
prepared a new series of unsymmetrical dinuclear compounds, [NI][{trans-RuCh(Me2SO-S)}Ot-L){mer-
RuCI3(MezSO-S)(Me2SO-O)}] (L pyz (1), pym (2), Figure 2), whose negative charge is expected to
provide appreciable solubility in aqueous solution. By a similar synthetic approach we also prepared new
mixed-valence Ru(III)/Ru(II) dinuclear compounds of formula [NH4][{trans-RuCla(MezSO-S)}(t-
pyz){cis, cis,cis-RuCl2(MeSO-S)2(CO)}] (L- pyz (3), pym (4), Figure 2).
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Figure 2. Schematic representation ofthe unsymmetrical dinuclear compounds 1-4.
Beside the preparation and characterization of the novel unsymmetrical dinuclear compounds 1-4, in
this paper we also describe their chemical behavior in physiological solution and after complete reduction
(with ascorbic acid) to the corresponding Ru(II)/Ru(II) species.
MATERIALS AND METHODS
The bridging ligands were purchased from Aldrich and used as received. Electronic absorption spectra were
recorded in quartz cells with a Jasco UV/vis V500 spectrophotometer equipped with a Peltier thermostatic
unit. Infrared spectra were obtained on a Perkin-Elmer 983 G spectrometer. H-NMR spectra (D20, Aldrich)
were collected at 400 MHz on a Jeol EX 400 FT spectrometer; spectra were recorded at room temperature
with 2,2-dimethyl-2,2-silapentane-5-sulfonate (DSS) as an internal standard. An inversion recovery pulse
sequence (n r- n/2) was applied for recording the spectra of the paramagnetic compounds (spectral window
30.000 Hz, pulse delay 0.5 s); with : 100 ms the resonances of molecules not coordinated to Ru(III) were
negative, while those of the coordinated ligands were positive. A 0.1 mol dm
3 pH* 7.4 phosphate-D20
buffer (pH meter reading from D20 solutions) containing 0.9% NaCI was used for NMR experiments aimed
to monitor the chemical behavior ofthe dimers in physiological solution.
The complexes [(Me2SO)2H][trans-RuCl4(Me2SO-S)2] [6], mer,cis-RuCl3(MezSO-S)(Me2SO-O)(pyz) [3],
mer,cis-RuCl3(Me2SO-S)(Me2SO-O)(pym) [3], cis,fac-RuCl2(Me2SO)3(CO) [7], cis, cis,cis-RuCl2(MezSO-
S)2(CO)(pyz) [7], and cis, cis,cis-RuClz(MezSO-S)z(CO)(pym) [7] were prepared according to the reported
procedures.
Preparation of [NH4][trans-RuCI4(Me2SO-S)2]. A 0.096 g amount of NH4CI (1.80 mmol) dissolved in 0.3
mL of water was added under stirring to a clear orange-red solution of [(MezSO)2H][trans-RuCl4(MezSO-S)2]
(0.50 g, 0.90 mmol) in aqueous ethanol (0.3 mL ofHO and 22.5 mL of ethanol). A deep-orange precipitate
formed in a few minutes; after standing overnight at 4 C, it was collected by filtration, washed with cold
acetone, and diethyl ether, and vacuum dried at ambient T (0.29 g, 78%). Found C, 11.4; H, 3.82; N, 3.23%.
C4H16NCI402S2Ru requires C, 11.5; H, 3.86; N, 3.35%. UV/vis (Lmx, nm) in HO: 398, 465.1H NMR (D20,
ppm, 400 MHz): -16.7 (br, MezSO-S).
Preparation of [NH4][{trans-RuCI4(Me2SO-S)}Otpyz){mer-RuCl3(Me2SO-S)(Me2SO-O)}] (1). A 0.053 g
amount of mer,cis-RuCl3(Me2SO-S)(Me2SO-O)(pyz) (0.12 mmol) dissolved in 7 mL of CHCI3 was added to
a methanol solution (7 mL) of [NH4][trar/s-RuCLl(Me2SO-S)2] (0.063 g, 0.15 retool). A red crystalline
precipitate formed within two days at ambient temperature, and was then collected by filtration, washed with
cold methanol and diethyl ether, and vacuum dried at ambient T (0.044 g, 47%). According to elemental
analysis and NMR spectroscopy the product contains one CH3OH molecule of crystallization; found C, 16.1;
o o H, 3.60; N, 5.04%. CllH3oN3CITO4S3Ru2 requires C, 16.2; H, 3.71; N, 5.15%. UV/vis (Xmx, nm) in H.O: 381.
1H NMR (D20, ppm, 400 MHz): 9.9 (br, Me_SO-O), -14.2 (br, Me2SO-S). IR (KBr, cm"): v(S-O) 1111 (vs,
Me2SO-S), 906 (vs, MezSO-O); v(Ru-O) 519 (m); v(Ru-S) 426 (m); v(Ru-Cl) 338 (vs).
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Preparation of [NH4ll{trans-RuCl4(Me2SO-S)}(lx-pym){mer-RuCl3(Me2SO-S)(Me2SO-O)}l (2) The
complex was prepared by the method used for 1 (yield 37%). According to elemental analysis and NMR
spectroscopy the product contains one CH3OH molecule of crystallization; found C, 16.0; H, 3.61; N, 5.07%.
CllH30N3CI704S3RuE requires C, 16.2; H, 3.71; N, 5.15%. UV/vis (kmx, nm) in H20: 385. 1H NMR (D20,
ppm, 400 MHz): 11.4 (br, Me2SO-O), -9.1 (br, pym), -14.4 (br, Me2SO-S). IR (KBr, cml): v(S-O) 1093 (vs,
Me2SO-S), 906 (vs, MeESO-O); v(Ru-O) 501 (m); v(Ru-S) 428 (m); v(Ru-Cl) 335 (vs).
Preparation of [NH4][{trans-RuCl4(Me2SO-S)}Ot-pyz){cis,cis,cis-RuCl(Me2SO-Sh(CO)}] (3). A 0.05 g
amount of cis, cis,cis-RuCIE(Me2SO-S)E(CO)(pyz) (0.115 mmol) dissolved in 7 mL of CHCI3 was added to a
methanol solution (5.5 mL) of [NH4][trans-RuCI4(MeESO-S)E] (0.054 g, 0.13 mmol). An orange precipitate
formed within two days at 4 C and was then collected by filtration, washed with cold methanol and diethyl
ether, and vacuum dried at ambient T (0.032 g, 35%). According to elemental analysis the product contains
one HEO molecule of crystallization; found C, 16.2; H, 3.25; ,N, 5.07%. CH2sN3CI6OsS3RuE requires C,
16.3; H, 3.45; N, 5.18%. UV/vis (x, nm) in HEO: 471,402. ’H NMR (DEO, ppm, 400 MI?Iz,): 2.82, 2.73,
2.45, 2.13 (s, MeESO-S--Ru(II)), -0.4 (br, pyz), -13.8 (br, MeESO-S-Ru(III)). IR (KBr, cml): v(CO) 2007
(vs); ,(S-O) 1123 (vs, Me2SO-S); v(Ru-S) 429 (rn).
Preparation of [NH4][{trans-RuCI4(MeSO-S)}(lz-pym){cis,cts,cis-RuCl2(MezSO-S)2(CO)}] (4). The
complex was prepared by the method used for 3 (yield 34%). Found C, 17.0; H, 3.35; N. 5.30%.
CIHE6N3CI604S3Ru2 requires C, 17.0; H, 3.38; N, 5.42%. UV/vis (nx, nm) in HEO: 471, 402. tH NMR
(DEO, ppm, 4,00 MHz): 3.26, 3.11 (s, MeESO-S-Ru(II)), 7.0, 3.4, -1.0 (br, pyre), -14.0 (br, MeESO-S-Ru(III)).
IR (KBr, cm"): v(CO) 2007 (vs); v(S-O) 1123 (vs, MeESO-S); v(Ru-S) 429 (m).
Crystallography
Crystal data for [NH4l[{trans-RuCli(Me2SO-S)}(lx-pyz){mer-RuCl3(MeSO-S)(MeSO-O)}l.CHOH (1)
Empirical formula, CH30C17N304Ru2S3. M 814.85; System, triclinic; Space group, P-l; a_ 8.523(1); b
12.173(4);=
14.553(4)/; ct 90.971(2"); I 95.44(1); 7 107.94(2); Vol. 1428.3(6) A; z 2;D
1.895 g cm ;/ (Mo-Kct) 1.954 mm" F(000) 808; of 6858 measured data (room temperature, 20max 56),
6588 were unique (Rint 0.0278), 4818 observed [I > 20 (/)]; 282 parameters; RI(F) 0.0509; wR2(F2)
0.1724; AF max, min: 1.473, -1.492 eA3. Deposition number CCDC 156559.
Structure determination
The dataset was collected at room temperature on an Enraf-Nonius CAD4 diffractometer, equipped with
graphite monochromator and Mo-Kct radiation (k 0.71073 A). Intensities data were corrected for Lorentz-
polarization effects and absorption through an empirical ap-scan method. The structure was solved by
conventional Patterson and Fourier technique [8] and refined by full-matrix anisotropic least-squares method
[9]. A molecule of methanol was located on the AF map with the oxygen atom disordered over two positions
refined to occupancies of 0.76 and 0.24. All the calculations were performed using the WinGX System, Vet
1.63 [lO].
RESULTS AND DISCUSSION
Preparation of unsymmetrical monoanionic Ru(lll) dinuclear compounds.
The synthesis of unsymmetrical monoanionic Ru(III) dinuclear species of formula [{trans-
RuCI4(MeESO-S)}(Ia-L){mer-RuCI(Me2SO-S)(MeESO-O)}]" requires a stepwise reaction in which the
bridging ligand L is bound first to one Ru(III)-Me2SO precursor, either anionic [trans-RuCl4(Me2SO-S)E]’, or
neutral mer-RuCl(MeSO), and the resulting complex is then treated with the complementary fragment
(Scheme 1).
Scheme 1. Reactivity pathways leading to unsymmetrical monoanionic Ru(III)/Ru(III) dinuclear species of
formula [{trans-RuCl4(MeESO-S)}(t-L){mer-RuCl3(Me2SO-S)(Me2SO-O)}] (L pyz); Q/ represents a
generic cation.
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Regardlesss of the pathway chosen, in the crucial step an anionic Ru(III) species has to react with a
neutral species and the choice of the most appropriate solvent is of paramount importance. We focused on
pyz and pym ligands and found that their coordination to the neutral precursor mer-RuCl3(MezSO)3, followed
by treatment with the anionic fragment [trans-RuCl4(Me2SO-S)2], gives best results. Firstly we found that
treatment of [NEt4][trans-RuCl4(Me2SO-S)z] with mer,cis-RuCl3(MezSO-S)(Me2SO-O)(pyz) in chloroform
leads to [NEt4][{trans-RuCl4(Me2SO-S)}(t-pyz){mer-RuCl(Me2SO-S)(Me2SO-O}] in good yield; however
this species is unsoluble in water and thus not suited for our purposes. Atter screening other cations and
solvents, we found that the best results were obtained with the ammonium salt [NH4][trans-RuCl4(Me2SO-
S)2] in methanol/chloroform mixtures. A proper choice of the methanol/chloroform ratio allowed us to obtain
the unsymmetrical dinuclear species [NHa][{trans-RuCla(Me2SO-S)}(t-pyz){mer-RuCl3(Me2SO-S)(Me2SO-
O)}] (1) in pure form even though with relatively low yield; larger amounts of chloroform induced the co-
precipitation of the corresponding dianionic symmetrical dimer [NH4]2[{trans-RuCl4(Me2SO-S)}2(tt-pyz)],
while larger amounts of methanol favored the co-precipitation of the neutral dimer [{mer-RuCl3(Me2SO-
S)(Me2SO-O)}2(lx-pyz)].
Complex 1 is fairly soluble in aqueous solution and was fully characterized by elemental analysis and
spectroscopic techniques; the 1H NMR spectrum of I (D20) shows the typical broad resonances at about 6
14 and 10 for S-bonded and O-bonded dimethylsulfoxide, respectively, while the resonances of the bridging
pyrazine protons are broadened beyond detection by the two close paramagnetic Ru(III) centers. The NMR
spectrum of the corresponding dinuclear species with pyrimidine, 2, shows also a rather broad and weak
resonance at 6 -9 attributed to H5, i.e. the proton of the bridging pym ligand which is further removed from
the Ru(III) nuclei. The X-ray structure of I was also determined.
Crystal structure of [NH4] {trans-RuCl4(Me2SO-S)}(t-pyz){mer-RuCla(Me2SO-S)(Me2SO-O)}
CH3OH (1).
The crystal of I is built up by complex and ammonium ions, and disordered molecules of methanol.
Both the Ru(III) ions, linked by the pyrazine ligand, display a pseudo-octahedral coordination (Figure 3). The
four chlorides at Ru(1) result almost eclipsed with the chlorides and the oxygen donors at Ru(2), with the
pyrazine oriented in such a way to bisect approximately one CI-Ru-CI bond angle. The Ru-CI bond lengths
fall in a range from 2.328(3) to 2.377(2) A.
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Figure 3. Perpective view of the dinuclear anion of [Nl][{trans-RuCla(Me2SO-S)}(l-pyz){mer-
RuCI3(Me2SO-,I(Me:SO-O)}] (I) (thermal ellipsoids at 50% probability level). Relevant bond distances ()
an angles (o): u()-() ;.0;(6), rtu()-s() ;.;9(;), rtu(;)-(;) ;.07(6), u(;)-s(;) ;.;73(;),
Ru(.)-o(3) 9_.048(5), Ru-C range from 9..39.8(3) to 9..377(9.); ()-Ru()-S() 75.(9_), c(4)-Ru()-C(9.)
177.54(9), CI(3)-Ru(1)-CI(1) 177.65(8), N(2)-Ru(2)-S(2) 177.4(2), O(3)-Ru(2)-CI(6) 175.8(2),
(7)-u(;)-c() 75.6;(9).
The arrangements of the Me2SO-S ligands are different, and the orientation might account for the
difference of about 0.02 A observed in the Ru-S bond distances (Ru(2)-S(2) 2.273(2) A, Ru(1)-S(1)
2.291(2) A) [11]. In fact, in one case the conformation is that usually found in Ru-(Me2SO-S) complexes
[12], with the O-S bond nearly eclipsed with the equatorial Ru(2)-O(3) bond. The torsion angles
O(3)-Ru(2)-S(2)-O(2) and CI(3)--Ru(1}-S(1)-O(1) are 2.6(5) and 42.1(4), respectively. The S-coordinated
ligands, like the free sulfoxides, are able to give rise to H-bonding with protic solvents [13]. In the present
case, the sulfoxide oxygen O(1) interacts electrostatically with two ammonium ions at 2.93 and 2.96 A,
leading to a lengthening of the S(I)-O(1) bond distance (1.489(6) A), with respect to the value of 1.451(7) A
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observed for S(2)-O(2). These interactions might be also responsible for the elongation detected in the
Ru-S(I) bond length. As for the conformation of the Me2SO-O, the torsion angles Ru-O-S-C of about
+128 indicate a trans-trans orientation of the methyl groups, which correponds to a minimum in the strain
energy profile [12]. The structure of the anion results slightly bowed along the Ru-pyrazine-Ru vector, as
evidenced by the dihedral angles made by the best fit planes through the N base (r.m.s. 0.013) and the Ru(1)
and Ru(2) equatorial mean planes of 81.4(2) and 87.8(2), respectively, the former being considerably apart
from the ideal value of90
Overall, the structural parameters of compound 1 are comparable to those previously reported by us
for the symmetrical dinuclear Ru complexes oftype a and b [3].
Preparation of mixed-valence monoanionic Ru(lll)/Ru(ll) dinuclear compounds.
With a synthetic procedure similar to that described for 1 and 2, we prepared also mixed-valence
monoanionic Ru(lll)/Ru(ll) dinuclear compounds of formula Ha][{trans-RuCla(Me2SO-S)}(t-
L){cis, cis,cis-RuCl2(Me2SO-S)2(CO)}] (L pyz (3) and pyre (4)); the bridging ligand L was first mono-
coordinated to the Ru(ll) precursor cis,fac-RuCl2(Me2SO)3(CO) and the resulting neutral complex cis, cis, cis-
RuCI(MeSO-S)2(CO)(L) [7] was treated with [NH4][trans-RuCla(Me2SO-S)2] in a chloroform/methanol
mixture (Scheme 2).
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Scheme 2. Reactivi pathway leading to mixed-valence monoanionic Ru(III)u(II) dinuclear compound
][ {trans-RuCh(MeSO-}(-pyz) {cis, cis,cis-RuGI(MeSO-(CO)} (3).
Complexes 3 and 4 are fairly soluble in aqueous solution. The D O HNMR specm ofcomplex 3
is characterized by a broad resonce at ca. 6 =-14, aibuted to the sulfoxide S-bonded to the Ru(III) unit,
d by four sher resonances beeen 6 2.13 and 2.82, aibuted to the four ditereotopic methyls of the
o inequivalent sulfoxides S-bonded to the Ru(II) fragment; with respect to the nodal region for MeSO-S
coordinated to Ru(II) (6 3.3 + 3.6), these resonances are upfield shifted of about ppm by the nearby
paramagnetic Ru(III) nucleus. Applying an inversion recove pulse sequence (n-x-n/2) we found that all
four Ru(IIMeSO-S resonances are positive for x 100 ms, while theo more downfield signals become
negative for x 50 ms (Figure 4); such resonances were thus aibuted to the MeSO-S ans to pyz, whose
protonse expected to have longerT relaxation times theye the hest from the paragnetic Ru(III)
center.
MeSS-Ru(llI)
MeSO-S-Ru(II)
pyz-Ru(II) Me2SO-S-Ru(III)
Figure 4. H NMR spectra of [NH4][{trans-RuCl4(Me2SO-S)}Ot-pyz){cis, cis,cis-RuCl(Me2SO-
S)2(CO)}] (3) recorded in D20 using the inversion-recovery pulse sequence with x 100 ms (top) and x 50
ms (bottom).
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Finally, a broad and relatively weak peak at b -0.4 was attributed to the two pyz protons closest to
the Ru(II) necleus, while the resonance of the other two protons is broadened beyond detection by the nearby
Ru(III) center.
Chemical behavior in physiological solution.
Aqueous solutions of the dimeric species 1-4 are characterized by a rather strong absorption band
5000 / 9000 dm mol
"1 cm1) in the visible region of the electronic spectrum (380+400 nm), attributed to a
charge-transfer from the chloride ligands to Ru(III). The time profiles of the visible spectra were used to
investigate the chemical behavior of 1-4 at physiological pH.
The spectral changes of the symmetrical dinuclear species a at pH 7.4 were relatively simple and
attributed to stepwise chloride hydrolysis from both Ru(III) centers [3]; conversely, for 1 and 2 a general
decrease of the main absorption band, not accompanied by the formation of any new clear spectral feature,
was observed. When the chemical behavior of I was monitored by H NMR spectroscopy, the resonance of
free dimethylsulfoxide at 6 2.72 increased with time; dissociation of the O-bonded ligand prevailed, as its
resonance decreased faster than that of Me2SO-S. Moreover, even though no relevant fragmentation of the
dinuclear structure was observed, relatively sharp resonances increased with time at b 2.55 and 1.90, which
might be attributed to Me2SO coordinated through O and through S, respectively, to a Ru(II) center in a
mixed-charge dinuclear species; thus, partial self-reduction of the RuCI3(MezSO)2 half of the dimeric
compound is likely to occur. A similar self-reduction process has been already hypothesized for explaining
the chemical behavior of the mononuclear species RuCI3(MezSO)3 in aqueous solution [6]. Overall, the
spectral behaviors of 1 and 2 were attributed to multiple and contemporaneous hydrolytic processes
concerning chloride and dimethylsulfoxide ligands, and occurring with relatively slow rates (hours),
accompanied by partial self-reduction ofthe neutral RuCI3(Me2SO)2 fragment.
The spectral changes observed for 3 and 4 were more straightforward and qualitatively very similar to
those observed for NAMI-A under the same conditions and were attributed to stepwise chloride hydrolysis
from the Ru(III) fragment only. Figure 5 reports the spectral variations for 4; in the first step, which is
complete in ca. 90 min at 25.0 C, the main absorption band at 400 nm is gradually replaced by a new band at
350 rim, typical of a mer-RuC13 unit, which was thus attributed to the neutral [{mer-RuCl3(HzO)(Me2SO-
S)}(t-L){cis, cis,cis-RuCl2(Me2SO-S)2(CO)}] species. The clean isosbestic point at 375 nm in the visible
spectra, supported by time-driven H NMR spectra under the same conditions, indicates that no relevant
fragmentation of the dinuclear structure occurs during this step. The first hydrolysis is followed by a slower
step that involves a decrease of the 350 nm band and was attributed to the hydrolysis of a second chloride
from the Ru(III) fragment.
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Figure 5. Spectral changes in the visible region during hydrolysis of the first chloride from [NH4][{trans-
RuCl4(Me2SO-S)}(t-pym){cis, cis,cis-RuCl(Me2SO-S)2(CO)}] (4) (25.0 C, 0.1 mol dm
3 phosphate buffer,
pH 7.4, 0.9% NaCI, [4] 10
-4 mol dm3, scan time interval 30 min).
Effect of biological reducing agents.
As in the case of the corresponding dianionic and neutral dinuclear species, [{trans-RuCl4(Me2SO-
S)}2(x-L)]
2" (a) and [{mer-RuCI3(Me2SO-S)(Me2SO-O)}2(t-L)] (b), we found that addition of one equivalent
of ascorbic acid to a physiological solution of either 1 or 2 led to the immediate and complete reduction to
Ru(II) species, as indicated by NMR evidence. The case of I will be described in more detail. Comparison
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with the 1H NMR spectra of the reduced forms of the dinuclear and mononuclear reference compounds
[{trans-RuCl4(Me2SO-S)}2(t-pyz)]2", [{mer-RuCl3(Me2SO-S)(Me2SO-O)}2(t-pyz)], [trans-RuCl4(Me2SO-
S)(pyz)]’, [mer-RuCl3(Me2SO-S)(Me2SO-O)(pyz)], [trans-IuCl4(Me2SO-S)2]’, and [mer-RuCI3(Me2SO-
S)2(Me2SO-O)], allowed us to assign most of the resonances of the most abundant species according to the
following general rules: 1) reduction involves O to S linkage isomerization of the equatorial Me2SO-O ligand
accompanied by its partial dissociation (ca. 25%); 2) chloride hydrolysis from the mer-RuCl3(Me2SO-S)
fragment occurs selectively in the position trans to Me2SO-S; 3) resonances ofMe2SO-S methyl groups occur
at fi 3.6 + 3.7 when the sulfoxide is bound to [{mer-RuCl3(Me2SO-S)(H20)}(1/2t-pyz)] unit and at {3 3.3
+ 3.5 when bound to [{mer-RuCl3(Me2SO-S)2}(1/2t-pyz)] unit; 4) the resonances of pyrazine are indicative
of its mode of coordination: terminal (multiplets at 9.2 -’. 9.5 (H2,6) and at {3 8.6 -: 8.9 (H3,5)) or
bridging ({3 9.3 -.’- 9.8); 5) protons of bridging pyz resonate as a singlet when the two Ru(II) units are equal
to one another and as two equally intense multiplets when they are different.
The spectrum of 1 taken immediately after reduction is quite complicated; the region of pyrazine
resonances (Figure 6) indicates the presence of at least four non-symmetrical and of one symmetrical (singlet
at 15 9.65) dinuclear species. The spectrum, however, is in rapid evolution and after 15 min it becomes
considerably simpler, with two main species, one symmetrical (IN) and the other nonosymmetricai (IC), in a
ca. 1:3 ratio (Figure 6).
1B’
1M
IN
1C+IB
1N 1C 1C
10.0 9.9 9.8 9.4 9.:3 9.2 9.1
Figure 6. Region of the pyrazine resonances in the IH NMR spectrum of [NI-h][{trans-RuCh(Me2SO-S)}(t-
pyz){mer-RuCl3(Me2SO-S)(Me_SO-O)}] (1)taken immediately after reduction with ascorbic acid (top) and
after 15 min (bottom) (D20, phosphate buffer pH* 7.4). See Scheme 3 for labeling scheme. X indicates a
mononuclear species.
The overall chemical behavior of 1 after reduction is summarized in Scheme 3. Both the trianionic
species IA and 1M obtained upon reduction of 1 (IM derives from dissociation of the equatorial Me2SO
ligand) hydrolyse quite rapidly (minutes) one chloride. Chloride hydrolysis occurs with comparable rates
from the RuCh and from the mer-RuCl3(Me2SO-S) fragments, thus the time-profiles of the transient species
1B and IB’ are similar; hydrolysis from the mer-RuCl3(H20) fragment is much slower. Species 1C and IN
are by far the most abundant between 15 and 60 min after reduction; for longer observation times, formation
of species ID and 10, derived by further hydrolysis of a chloride from IC and IN, respectively, occurs (the
geometry, either is or trans of the Ru(H20)2 fragment in ID and 10 was not determined). Moreover, the
resonances of mononuclear species, of free pyrazine and dimethylsulfoxide become increasingly relevant.
Formation of all possible mononuclear species (either bearing or not terminally coordinated pyz) in
comparable amounts indicates that fracture ofboth Ru-pyz bonds is equally likely.
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IM IN 10
Scheme 3. Main species found in physiological solution within 2h after reduction of [NH4][{trans-
RuCl4(MeESO-S)}(p-pyz){mer-RuCl3(Me2SO-S)(Me2SO-O)}] (1) by addition of one equivalent of ascorbic
acid (25 C).
The behavior of the pyrimidine compound 2 after reduction is qualitatively very similar to that of 1,
except that the chloride hydrolytic processes are ca. 20% faster and also the formation of monomeric species
is more pronounced.
In both cases, the reduction of the dimeric compounds is also accompanied by a remarkable increase
in solubility due to the increased charge and by a dramatic change in color, from orange to dark red (the main
absorption band at 380 nm is replaced by an intense and broad band at 447 nm, attributable to a t2g --* g*
charge-transfer absorption as in the case ofthe symmetrical dimeric species [3]).
Treatment. of physiological solutions of the mixed-valence dinuclear species [{trans-RuCl4(MeSO-
S)}(t-L){cis, cis,cis-RuCb(Me2SO-S)2(CO)}] (L pyz (3) and pym (4)) with one equivalent of ascorbic acid
led similarly to the complete and rapid reduction of the Ru(III) fragment. Also in this case the chemical
behavior of the reduced species was investigated mainly by IH NMR spectroscopy. The behavior of 3 after
reduction is summarized in Scheme 4 and is substantially similar to that of the corresponding monomeric
species [trans-RuCl4(MeSO-S)(pyz)]" [3] because the cis, cis,cis-RuCl2(MeSO-S)(CO) fragment is inert and
all hydrolytic processes occur on the other half of the dimer. Also fracture of the Ru(II)-pyz bond occurs
exclusively at the site of the reduced Ru atom, generating the mononuclear species cis, cis,cis-RuC12(MeSO-
S)2(CO)(pyz) (identified by comparison with the resonances of a pure sample).
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Scheme 4. Main species found in physiological solution within 2h after reduction of [NH4][{trans-
RuCl4(MezSO-S)}(t-pyz){cis, cis,cis-RuCl2(Me2SO-S)2(CO)}] (3) by addition of one equivalent of ascorbic
acid (25 C).
In more details, the dianionic species 3A disappears within 20 min after reduction, generating the
monoanion [{mer-RuCl3(MezSO-S)(HzO)}(t-pyz){cis,cis,cis-RuCl2(MezSO-S)z(CO)}]" (3B), which is the
prevailing species in the first hour after reduction. 3B either hydrolyzes a further chloride to give the trans
and cis geometric isomers 3C and 3C’ in a ca. 1:2 ratio (in this case the pyz resonances of the two isomers
are distinguishable, but assignment to each isomer was not possible) or splits into mononuclear species which
represent 20% of the total after 2.5 h. The pyrimidine dinuclear species 4 behaves similarly to 3 upon
reduction, except that the hydrolytic processes are more rapid and the splitting of the Ru-N bond, which
yields selectively cis, cis,cis-RuClz(MeSO-S)z(CO)(pym), occurs to a larger extent (50% of mononuclear
species 3h after reduction). The reduction of 3 and 4 involves an increase in solubility and a change of color
similar to that observed upon reduction ofthe Ru(III)/Ru(III) dimeric species 1 and 2.
In conclusion, the chemical behavior of the unsymmetrical Ru(III)/Ru(III) species [{trans-
RuCI4(Me2SO-S)}(t-L){mer-RuC13(Me2SO-S)(Me2SO-O)}] (L pyz (1), pym (2)) after treatment with
biological reducing agents in physiological solution resembles that of the corresponding dianionic and neutral
dinuclear species, [{trans-RuCl4(MezSO-S)}z(t-L)]
z" and [{mer-RuCl(MezSO-S)(MezSO-O)}z(t-L)],
respectively. As reported in Scheme 3 (and not considering fragmentation) reduced 1 and 2, after chloride
and/or sulfoxide hydrolysis, are bi-functional binders at one site and mono-functional binders at the other
(coordinated water is a labile ligand); thus, their adducts with biological targets are likely to be different from
those obtained upon coordination of the corresponding mononuclear species. On the other hand, the mixed-
valence dinuclear compounds [{trans-RuCh(MezSO-S)}(t-L){cis, cis,cis-RuClz(Me2SO-S)2(CO)}] (L pyz
(3) and pyre (4)), owing to the great inertness of the cis, cis,cis-RuCl2(Me2SO-S)2(CO)(1/2tt-L) fragment,
both before and after reduction behave substantially like the corresponding mononuclear species [trans-
RuCI4(Me2SO-S)(L)]" in which the terminally bonded L ligand can be considered as bearing a bulky
substituent on the otherN atom.
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